STOCK TITAN

Drugs Made in America II proposal values Alpha AI at $600M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Drugs Made in America Acquisition II Corp. (DMII) reported a preliminary, nonbinding combination proposal accepted in principle by Alpha AI Biotech Group on October 30, 2026. It contemplates a $600 million pre-money valuation, payable in 60,000,000 DMII ordinary shares at $10.00 each, plus up to 30,000,000 earn-out shares in two equal tranches tied to $12.50 and $15.00 share-price thresholds within 24 months after closing. Due diligence, audited financial statements, definitive agreements and approvals remain conditions; no definitive agreement has been executed.

DMII received a $250,000 installment under an investor’s $1,400,000 convertible-note commitment; $700,000 has been funded and $700,000 remains. The notes and installment are to be consolidated into a $700,000 note maturing June 30, 2027, unless earlier converted. Upon a business combination, the investor may elect to convert it into combined-entity shares at a 35% discount to market price at conversion. A 30-day standstill expires on or about December 3, 2026 unless extended or terminated; it restricts only consummation of competing transactions and permits alternative discussions.

Filing Explained

The filing clarifies that the investor’s remaining $700,000 commitment under the existing financing agreement is not contingent on approval or closing of the proposed Alpha combination, so that funding commitment remains separate from whether the combination proceeds.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Proposed pre-money valuation $600 million Alpha AI Biotech Group, under the preliminary proposal
Proposed share consideration 60,000,000 DMII ordinary shares at $10.00 per share Consideration contemplated for Alpha
Earn-out consideration Up to 30,000,000 ordinary shares Two equal tranches tied to $12.50 and $15.00 share-price thresholds within 24 months after closing
Convertible-note financing commitment $1,400,000 Commitment by the investor under the Agreement
Funding status $700,000 funded; $700,000 remains Under the $1,400,000 commitment, following the November 6, 2026 installment
Consolidated note $700,000 principal; matures June 30, 2027 The Bridge Note, Second Note and $250,000 installment are to be consolidated
Conversion discount 35% At the investor’s option upon completion of a business combination, based on market price at conversion
Standstill 30 days; expires on or about December 3, 2026 May be extended or terminated earlier; limits consummation of a competing transaction
pre-money equity valuation financial
"pre-money equity valuation of Alpha of $600 million"
Value placed on a company’s equity immediately before a new round of outside financing; it represents how much the company is considered worth before the fresh cash is added. It matters because it sets the price per share and determines how much ownership new and existing shareholders will hold after the deal, like agreeing the size of a pie before adding extra slices to be shared among more people.
earn-out consideration financial
"up to 30,000,000 additional ordinary shares as earn-out consideration"
Earn-out consideration is money a buyer agrees to pay a seller after a takeover only if the acquired business meets specific future targets, such as revenue, profit, or product milestones. Think of it like a performance bonus that shifts some purchase price into the future; it matters to investors because it changes how much risk and potential value they should assign to a deal and can affect future cash flows, reported earnings, and ownership incentives.
Convertible Notes Financing financial
"the Investor committed $1,400,000 of convertible notes financing"
conversion price financial
"conversion price equal to a 35% discount to the market price"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
standstill regulatory
"the Proposal’s limited 30-day standstill"
A standstill is a temporary agreement in which one party agrees to pause certain actions — such as buying more shares, launching a takeover bid, or enforcing debt claims — for a set period. For investors this matters because it freezes changes in ownership or legal pressure, giving markets time to absorb information and reducing short-term volatility; think of it as pressing a pause button so everyone can negotiate or reassess without sudden moves.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the proposed terms of DMII’s business combination with Alpha?

The proposal contemplates 60,000,000 DMII ordinary shares at $10.00 per share for Alpha’s $600 million pre-money valuation, plus up to 30,000,000 earn-out shares in two equal tranches linked to $12.50 and $15.00 share-price thresholds during the 24 months after closing. It remains nonbinding and subject to due diligence, definitive agreements and approvals.

How much of DMII’s convertible-note financing has been funded?

The investor has funded $700,000 of the $1,400,000 commitment, leaving $700,000 available under the agreement. The latest $250,000 installment was received November 6, 2026. The notes and installment are to be consolidated into a $700,000 note maturing June 30, 2027, unless earlier converted; upon a business combination, the investor may elect conversion at a 35% discount to market price at conversion.

What does the standstill in DMII’s Alpha proposal restrict?

The standstill restricts only consummation of a competing transaction and expires on or about December 3, 2026 unless extended or terminated earlier. It does not prevent either party from evaluating or negotiating alternatives, and the board’s approval of the standstill does not approve the business combination.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 29, 2026

 

DRUGS MADE IN AMERICA ACQUISITION II CORP.

(Exact name of registrant as specified in its charter)

 

Cayman Islands

 

001-42863

 

98-1815624

State or other jurisdiction

of incorporation

 

Commission

File Number

 

IRS Employer

Identification No.

 

420 Lexington Avenue, Suite 1402, New York, NY10170

(Address of principal executive offices, including zip code)

 

646-726-7074

(Registrant's telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Units, each consisting of one Ordinary Share and one Right to receive one-tenth (1/10) of one Ordinary Share

 

DMIIU

 

The Nasdaq Stock Market LLC

Ordinary Shares, par value $0.0001 per share

 

DMII

 

The Nasdaq Stock Market LLC

Rights, each entitling the holder to receive one-tenth (1/10) of one Ordinary Share

 

DMIIR

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

 

 

 

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

As previously disclosed in the Current Reports on Form 8-K filed on March 17, 2026 and April 3, 2026, Drugs Made in America Acquisition II Corp. (the "Company") and Tal Alpha Yezum Vekidum Asakim (2003) Ltd. (the "Investor") are parties to the Definitive Investment and Sponsor Transition Agreement dated March 23, 2026 and effective March 24, 2026 (the "Agreement"). Under the Agreement, the Investor committed $1,400,000 of convertible notes financing to the Company (the "Convertible Notes Financing"). The Investor previously funded $450,000 through an unsecured convertible note in the principal amount of $150,000 issued on March 11, 2026 (the "Bridge Note") and an Interim Convertible Note in the principal amount of $300,000 issued on March 30, 2026 (the "Second Note").

 

On November 6, 2026, the Investor funded a further $250,000 under the Convertible Notes Financing, and the Company has received those funds. Following this installment, $700,000 of the Convertible Notes Financing has been funded and $700,000 remains available under the Agreement.

 

It has been agreed between the Company and the Investor that the Bridge Note, the Second Note and the $250,000 installment will be consolidated into a single convertible promissory note in the principal amount of $700,000 (the "Consolidated Note"), which will replace the Bridge Note and the Second Note. The Consolidated Note will mature on June 30, 2027, unless earlier converted, extending the maturities of the Bridge Note and the Second Note, which would otherwise have fallen in December 2026. The Consolidated Note will have the same conversion features as the prior notes: upon completion of a business combination, it may, at the option of the Investor, be converted into shares of the combined entity at a conversion price equal to a 35% discount to the market price of such shares at the time of conversion. The Consolidated Note will represent a direct financial obligation of the Company.

 

Item 8.01. Other Events.

 

Preliminary Proposal

 

On October 29, 2026, the Company delivered to Alpha AI Biotech Group ("Alpha") a preliminary proposal regarding a potential business combination (the "Proposal"). Alpha acknowledged and accepted the Proposal in principle on October 30, 2026.

 

The Proposal contemplates a pre-money equity valuation of Alpha of $600 million, payable in 60,000,000 ordinary shares of the Company at $10.00 per share. Alpha shareholders could also receive up to 30,000,000 additional ordinary shares as earn-out consideration, in two equal tranches subject to share-price thresholds of $12.50 and $15.00 during the 24 months after closing.

 

The Proposal is subject to, among other things, satisfactory due diligence, audited financial statements, execution of definitive agreements, and required board, shareholder and regulatory approvals.

 

Limited Standstill

 

On November 3, 2026, the Company's Board of Directors approved the Proposal's limited 30-day standstill, which expires on or about December 3, 2026 unless extended or terminated earlier. The standstill restricts only the consummation of a competing transaction; it does not prevent either party from evaluating or negotiating alternatives. The Board's approval of the standstill does not constitute approval of any business combination.

 

 

2

 

 

 

Binding and Nonbinding Terms

 

The Proposal is a nonbinding expression of interest, except for its confidentiality provisions, the limited standstill and the funding acknowledgment described below.

 

Working Capital Financing; Relationship of Mr. Tal

 

In connection with the Proposal, the Investor acknowledged its continuing commitment under the Agreement, including the $250,000 installment funded on November 6, 2026 and described in Item 2.03 above. The Investor's funding commitment is not contingent on approval or closing of the proposed transaction with Alpha.

 

Alon Izidor Tal, the Chief Executive Officer of the Investor, is also a director of Alpha and acknowledged the Proposal on Alpha's behalf. The Agreement also contains provisions relating to a transition of the Company's sponsor, as described in the Current Report on Form 8-K filed on April 3, 2026. The Company's Board of Directors, which consists entirely of independent directors, was aware of Mr. Tal's relationships with both Alpha and the Investor when it approved the standstill.

 

No Assurance

 

No definitive business combination agreement has been executed. There can be no assurance that a definitive agreement will be executed, that the proposed terms will be maintained, that any earn-out shares will become issuable, or that any transaction will be consummated.

 

Forward-Looking Statements; Additional Information

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements about the proposed business combination with Alpha, its terms and valuation, the potential earn-out consideration, the expected timing of definitive agreements, and the Company's working capital financing. Words such as "may," "will," "expect," "intend," "contemplate," "potential" and similar expressions identify forward-looking statements. These statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond the Company's control. Actual results may differ materially.

 

Factors that could cause such differences include, among others: the inability to negotiate or execute definitive agreements; the results of due diligence, including verification of Alpha's assets, ownership, intellectual property and financial statements; changes to the proposed valuation or other terms; the amount of redemptions from the Company's trust account; the failure to obtain required board, shareholder or regulatory approvals; termination of the limited standstill; the availability of working capital financing; potential conflicts of interest, including Mr. Tal's relationships with both Alpha and the Investor; and the risks described in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update these statements, except as required by law.

 

 

3

 

 

 

Additional Information and Where to Find It

 

If a definitive agreement is executed, the Company [and/or Alpha] intends to file with the SEC [a registration statement on Form S-4 / Form F-4, which will include a proxy statement/prospectus] in connection with the proposed transaction. Shareholders of the Company are urged to read those documents, when available, because they will contain important information about the Company, Alpha and the proposed transaction. Those documents, when filed, will be available free of charge on the SEC's website at www.sec.gov or by directing a request to the Company at 420 Lexington Avenue, Suite 1402, New York, NY 10170.

 

Participants in the Solicitation

 

The Company, Alpha and their respective directors and executive officers may be deemed participants in the solicitation of proxies from the Company's shareholders in connection with the proposed transaction. Information about the Company's directors and executive officers is set forth in the Company's filings with the SEC. Additional information regarding the interests of participants, including the interests of Mr. Tal and the Investor, will be included in the proxy statement/prospectus if and when filed.

 

No Offer or Solicitation

 

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or the proposed transaction. It does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

4

 

 

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

DRUGS MADE IN AMERICA ACQUISITION II CORP.

 

 

 

 

 

Date: November 18, 2026

By:

/s/ Roger E. Bendelac

 

 

Name: 

Roger E. Bendelac

 

 

Title: 

Chief Executive Officer

 

 

 

5

 

Filing Exhibits & Attachments

5 documents

Keep reading